Medtronic PLC (MDT) reports robust revenue and EPS growth, driven by innovations in Cardiac Ablation and Leadless Pacing, ...

Medtronic Plc (NYSE:MDT) reported third-quarter 2025 sales of $8.29 billion, missing the consensus of $8.32 billion. The ...

Medtronic’s (NYSE: MDT) growth efforts and investments in medical technology innovation are starting to pay off. The ...

Medtronic Plc. shares slumped nearly 7.3% on Tuesday — their worst single-day decline since March 2020 — after the company's ...

Medtronic (MDT) stock slips as the company reaffirms full-year outlook after delivering mixed financial for Q3 fiscal 2025.

Reports Q3 revenue $8.29B, consensus $8.33B. “We delivered strong earnings this quarter, with significant improvements in both our gross margin ...

Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...

Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by ...

Medtronic's stock is probably not a jaw-dropping bargain at these prices, but it's an excellent business at a reasonable value. It's safe to call Medtronic a solid buy, especially if you're a ...

Medtronic's stock has been static, not delivering any gains for investors. Click here to find out why MDT stock is a Buy.

Medtronic stock was down stock was down today after its third-quarter revenue slightly missed the Wall Street analyst consensus.

Goldman Sachs analyst David Roman raised the firm’s price target on Medtronic (MDT) to $85 from $83 and keeps a Sell rating on the shares. The ...